Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 2.02, 7.01, 9.01 · 8-K

STAAR Surgical Company

STAANASDAQEQUITYCurrent

Results of Operations and Financial Condition · Regulation FD Disclosure

Item 2.02 Results of Operations and Financial Condition. On November 4, 2026, STAAR Surgical Company (the “Company”) published a press release reporting its financial results for the quarter ended October 2, 2026, a copy of which is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.

Filed Nov 4, 2026Accepted Nov 4, 2026, 4:03 PM ESTCIK 718937Accession 0000718937-26-000040
Share

Company context

STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for over 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer® Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICLs are clinically proven to deliver safe long-term vision correction without removing corneal tissue or the eye's natural crystalline lens. Its EVO ICL™ product line provides visual freedom through a quick, minimally invasive procedure.

Current securities

Recent company filings

  1. SCHEDULE 13G/A - filed by Point72 Asset Management, L.P. regarding STAAR SURGICAL CONov 16, 2026
  2. 10-Q filingNov 4, 2026
  3. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureOct 5, 2026
  4. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureSep 10, 2026
  5. 4 filingAug 18, 2026

Registered securities in this filing

STAAR SURGICAL CO · 8-K · Filed 2026-11-04

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common

Symbol
STAA
Exchange
NASDAQ
Classification
OTHER
Status
Current
Filing context

Context: C_08c0ccda-77bd-4291-ac05-c03e826b9083

Dimensions: Not supplied

Accession 000071893726000040 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 2.02, 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition. On November 4, 2026, STAAR Surgical Company (the “Company”) published a press release reporting its financial results for the quarter ended October 2, 2026, a copy of which is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. During a conference call and webcast scheduled to be held at 5:30 p.m. Eastern / 2:30 p.m. Pacific on November 4, 2026, the Company’s President and Chief Executive Officer and the Company’s Executive Vice President and Chief Financial Officer will discuss the Company’s results for the quarter ended October 2, 2026. The information furnished herewith pursuant to Items 2.02 and 7.01 of this Current Report, including Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in Items 2.02 and 7.01 of this Current Report shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing.
Filed exhibits (1)
EX-99.1 (by filename) staa-ex99_1.htm

Exhibit 99.1 STAAR Surgical Reports Third Quarter 2026 Results Net Sales of $83.4 Million in the Third Quarter Net Income of $5.6 Million, with GAAP EPS of $0.11 Adjusted EBITDA[1]of $14.4 Million, or $0.28 per Diluted Share Record Revenue of $270.5 Million in the First Three Quarters Net Income of $18.8 Million, or $0.37 per Diluted Share, in the First Three Quarters Adjusted EBITDA[1] of $58.8 Million, or $1.14 per Diluted Share, in the First Three Quarters LAKE FOREST, Calif. --(BUSINESS WIRE)--STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the third quarter ended October 2, 2026. The Company will host an earnings call and webcast today at 5:30 PM Eastern Time. Third Quarter and Year-to-Date 2026 Highlights Include: • Net sales down 12% Y/Y; up 21% excluding a 33-percentage point ($25.9 million) impact from previously deferred China sales recognized in the third quarter of 2025 • China sales of $39.3 million, down 30% Y/Y; up 31% excluding a 61-percentage point impact from the deferred China sales • EMEA…

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.